Switch theme
Sign up to access all valuation multiples
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.
2014
164
LTM Revenue $49.0M
LTM EBITDA -$54.9M
$105M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
scPharmaceuticals has a last 12-month revenue of $49.0M and a last 12-month EBITDA of -$54.9M.
In the most recent fiscal year, scPharmaceuticals achieved revenue of $36.3M and an EBITDA of -$77.6M.
scPharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See scPharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $13.6M | $36.3M | XXX | XXX | XXX |
| Gross Profit | n/a | $9.8M | XXX | XXX | XXX |
| Gross Margin | NaN% | 27% | XXX | XXX | XXX |
| EBITDA | -$46.1M | -$77.6M | XXX | XXX | XXX |
| EBITDA Margin | -339% | -213% | XXX | XXX | XXX |
| Net Profit | -$36.8M | -$54.8M | XXX | XXX | XXX |
| Net Margin | -271% | -151% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 1, 2025, scPharmaceuticals's stock price is $3.
scPharmaceuticals has current market cap of $128M, and EV of $105M.
See scPharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $105M | $128M | XXX | XXX | XXX | XXX | $-1.61 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 1, 2025, scPharmaceuticals has market cap of $128M and EV of $105M.
scPharmaceuticals's trades at 2.1x LTM EV/Revenue multiple, and -1.9x LTM EBITDA.
Analysts estimate scPharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for scPharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $105M | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | -1.4x | XXX | XXX | XXX |
| P/E | -1.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialscPharmaceuticals's NTM/LTM revenue growth is 91%
scPharmaceuticals's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, scPharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate scPharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for scPharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 167% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -213% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 68% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -123% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 33% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 247% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
scPharmaceuticals acquired XXX companies to date.
Last acquisition by scPharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . scPharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was scPharmaceuticals founded? | scPharmaceuticals was founded in 2014. |
| Where is scPharmaceuticals headquartered? | scPharmaceuticals is headquartered in United States of America. |
| How many employees does scPharmaceuticals have? | As of today, scPharmaceuticals has 164 employees. |
| Who is the CEO of scPharmaceuticals? | scPharmaceuticals's CEO is Mr. John H. Tucker. |
| Is scPharmaceuticals publicy listed? | Yes, scPharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of scPharmaceuticals? | scPharmaceuticals trades under SCPH ticker. |
| When did scPharmaceuticals go public? | scPharmaceuticals went public in 2017. |
| Who are competitors of scPharmaceuticals? | Similar companies to scPharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of scPharmaceuticals? | scPharmaceuticals's current market cap is $128M |
| What is the current revenue of scPharmaceuticals? | scPharmaceuticals's last 12-month revenue is $49.0M. |
| What is the current EBITDA of scPharmaceuticals? | scPharmaceuticals's last 12-month EBITDA is -$54.9M. |
| What is the current EV/Revenue multiple of scPharmaceuticals? | Current revenue multiple of scPharmaceuticals is 2.1x. |
| What is the current EV/EBITDA multiple of scPharmaceuticals? | Current EBITDA multiple of scPharmaceuticals is -1.9x. |
| What is the current revenue growth of scPharmaceuticals? | scPharmaceuticals revenue growth between 2023 and 2024 was 167%. |
| Is scPharmaceuticals profitable? | Yes, scPharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
